Zymeworks Inchares (NYSE:ZYME) Short Interest Increased By 0.28%

Zymeworks Inchares (NYSE:ZYME) recorded an increase of 0.28% in shares shorted. FINRA announced in December ZYME’s total 546,200 shares shorted. The 544,700 previous shares are up with 0.28%. With Average volume 63,500, ZYME’s previous position will take 9 days to recover. Float short on Zymeworks Inchares is 2.84%.

Ticker’s shares touched $13.14 during the last trading session after 0.08% change.Zymeworks Inc. has 117,323 shares volume, 1.53% up from normal. ZYME is uptrending and has moved 74.85% since December 8, 2017. ZYME outperformed by 59.23% the S&P500.

Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada.The firm is worth $419.91 million. The companyÂ’s lead product candidate include ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast, gastric, and ovarian cancers.Last it reported negative earnings. It is also developing ZW33, a bispecific anti-human epidermal growth factor receptor 2 antibody-drug conjugate that is in preclinical development stage for the treatment of breast and ovarian cancers.

For more Zymeworks Inc. (NYSE:ZYME) news announced briefly go to: Seekingalpha.com, Businesswire.com, Business.Financialpost.com, Seekingalpha.com or Streetinsider.com. The titles are as follows: “Zymeworks halted pending news – Seeking Alpha” announced on June 01, 2018, “Zymeworks Advances Clinical Candidate Incorporating Technology from Kairos Acquisition – Business Wire” on March 14, 2018, “Zymeworks to Present at Canaccord Genuity 38th Annual Growth Conference – Financial Post” with a publish date: August 02, 2018, “Arsanis and CohBar among Healthcare gainers; G1 Therapeutics and ReShape Lifesciences among the losers – Seeking Alpha” and the last “Zymeworks (ZYME) Reports Updated Clinical Data for Novel Bispecific Antibody, ZW25 – StreetInsider.com” with publication date: November 14, 2018.

Zymeworks Inc. (NYSE:ZYME) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.